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Introduction: An important issue in cancer therapy is the achievement of desired 
therapeutic response with the least adverse effects. To achieve this goal, targeted 
drug delivery systems were developed. Aptamers, mainly DNA/RNA aptamers, are 
the attractive affinity ligands for the cancer cell surface specific antigens. Besides, 
microRNAs are another type of therapeutic and diagnostic oligonucleotides that 
have been recently studied in various cancers. miRNAs are small double stranded 
RNAs with important roles in cell regulatory pathways. Profile changes of miRNAs 
can result in cancer development. External addition of miRNAs or their elimination 
using antagomiR can lead to the efficient treatment of related disease. Targeted 
delivery of therapeutic agents to the site of action with less adverse effects is the 
most challenging issue in anticancer chemotherapeutic agents as well as miRNA 
therapy. In addition, miRNAs stability in biological systems can be improved by 
targeting strategy. In this study, a cancer specific aptamer (anti-nucleolin aptamer) 
and a functional miRNA in cell growth and proliferation (miRNAlet-7d) were used 
in the development of targeted nano-molecules as an efficient anti-proliferative 
agent for cancer cells.  
 
Methods and Results: Sequences of A1411 aptamer and miRNA let-7d were 
extracted from related databanks and were chemically synthesized with amine and 
thiol modification in the 3' terminals or with a 17 nucleotides sticky extension at 3' 
terminal.  The sequences were conjugated covalently using SM(PEG)2 hetero-bi-
functional cross-linker or un-covalently by annealing the sticky ends. Conjugation 
was confirmed using polyacrylamide gel electrophoresis 15%. The serum stability of 
these two types of conjugates were evaluated using up to 48 h incubation of 
conjugates in human serum (AB
+
). Stability of covalent conjugate using SM(PEG)2 
linker was at least two hours more than the un-covalent one.   
Conclusions: Remarkable advantages of this nano-molecule were targeted and 
relative stable delivery of miRNA as the therapeutic agent with probable synergistic 
effect of two oligonucleotides of miRNA and aptamer in the proliferation inhibition 
of cancer cells.  
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